ArticleAudiology & neuro-otology2026
Dexamethasone Dosing of Human Perilymph Compared for Common Delivery Protocols Using Inner Ear Simulations.
Article in Audiology & neuro-otology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
<p>Introduction: Locally applied dexamethasone therapy of the inner ear is commonly used to treat disorders such as Meniere's disease and idiopathic sudden sensorineural hearing loss. Dexamethasone is also being used in conjunction with cochlear implantation to reduce electrode impedances and fibrous tissue formation around the implant. The variety of formulations currently in use makes it difficult to compare the dosing levels resulting from different therapies.
methodsWe have used the FluidSIM cochlear fluid simulation program to calculate perilymph and plasma dexamethasone levels achieved by a variety of dosing approaches used clinically in humans. Identical pharmacokinetic parameters for perilymph and plasma were used for each delivery condition.
resultsEach of the delivery protocols was calculated to generate therapeutic concentrations in perilymph, but the time course of influence differed markedly between them. Some protocols generate concentrations in the blood that are above therapeutic concentration, increasing the potential for systemic side effects. DISCUSSION: Detailed simulations of delivery procedures allow different approaches to be compared quantitatively, giving a measure of dosing efficiency and allowing the merits of each protocol to be compared. Cochlear implants provide the most efficient dosing, generating therapeutic concentrations in the cochlea with minimal systemic influence. For intratympanic delivery, Spiral Therapeutics SPT-2101 provides therapeutic concentrations in perilymph with minimal systemic dosing. Conventional IT therapy with dexamethasone phosphate provides brief therapeutic concentrations in perilymph but substantial systemic exposure, with plasma concentration calculated to exceed therapeutic levels. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.